Xanthinuria is a familial disorder of purine metabolism that results from a marked deficiency of xanthine oxidase (EC 1.2.3.2) activity. We report here the clinical and biochemical features of a new case of xanthinuria. Serum urate concentration was 0.8 mg/i 00 ml, urinary uric acid excretion was 16 mg per day, urinary oxypurme excretion was 1630 mol per day, and total purine excretion was 314 mg per day. After allopurinol was administered, total purine excretion was 323 mg per day and erythrocyte phosphoribosylpyrophosphate content was unchanged. The ratio (by wt) of xanthine to hypoxanthine in the urine was 4.6 before and 9.6 after allopurinol was administered to this patient. Both allopurinol and oxipurinol were detectable in urine. Orotic acid and orotidine excretion increased from undetectable amounts (<2 mg per day) to 47 and 86 mg per day, respectively. These data suggest that this xanthinuric subject has a markedly decreased xanthine oxidase activity, although some residual activity may be functional in vivo. It is probable that he re-utilizes purine so extensively that hypoxanthine phosphoribosyltransferase (EC 2.4.2.8) isvi rtually saturated with hypoxanthine and xanthine in vivo. In addition, these data indicate that the increase in orotic acid and orotidine seen in normal and gouty subjects taking allopurinol is not a direct consequence of xanthine oxidase inhibition, but probably an effect of allopurinol or one of its metabolites on pyrimidine biosynthesis.
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AddItional Keyphrases: inherited disorders #{149} purine and pyrimidine metabolism #{149} xanthinuria Xanthinuria is a disorder of purine metabolism that results from a marked deficiency of xanthine oxidase (EC 1.2.3.2) activity in hepatic tissue, small-intestinal mucosa, colostrum, and rectal mucosa (1) .
Although half the patients with this disorder are asymptomatic, about a third of them have nephrolithiasisand 10% have myopathy as a consequence of the derangement in purine metabolism (1) (8) , with bovine serum albumin as standard.
All chemicals were of the highest grade commercially available and their purity was based on data supplied by the manufacturer.
Results

amination,
including a detailed neurological examination, were within normal limits, except for mild icterus. Values for all laboratory data were normal except for the findings associated with hemolytic anemia and xanthinuria.
Routine urine analysis revealed a moderate number of crystals, which were digested by xanthine oxidase but not uricase. PP-ribose-P was extracted from the erythrocytes and assayed by use of adenine phosphoribosyltransferase (EC 2.4.2.7) (4).
Serum and urinary uric acid were determined by the uricase method (5) . Total oxypurines in the urine were determined as the difference between the uric acid concentration before and after xanthine oxidase was added to the sample (6).
Urine samples (2 ml) were applied to the Mark II ultravioletanalyzer as previously described (7).The compounds that were eluted from the column were Uric acid and oxypurine determinations. Table 1 lists the uric acid and oxypurine determinations performed while the patient was on the purine-free diet.
Serum urate by the uricase method averaged 0.8 mg/dl, with the highest value being 1.3 mg/dl. The daily excretion of uric acid averaged 16 mg, with a maximum of 26 mg. Total urinary oxypurines, determined as the amount of uric acid produced from hypoxanthine and xanthine present in the urine, averaged 1630 izmol per day. If we assume that hypoxanthine and xanthine had been totally converted to uric acid endogenously, this patient would excrete an average 314 mg of uric acid per day. This is less than the 418-469 mg of uric acid excreted per day, on the average, by the normal adult male (9).
Xanthine oxidase activity.
Enzyme activity was determined in both small intestinal and rectal mucosa. Xanthine oxidase activityin jejunal mucosa obtained from the patient was 5% as great as that found for a control subject. The xanthine oxidase activity in his rectal mucosa was 25% of that found for 15 control subjects. These data confirm the patient's deficiency of xanthine oxidase activity and establish the diagnosis of xanthinuria in this subject.
Effect of allopurinol on purine metabolism.
As mentioned above, total purine excretion on a purinefree diet averaged 314 mg per day, a value well below that for the normal man (9) . After 800 mg per day of allopurinol was administered, total purine excretion was unchanged (323 mg per day). This contrasts with the decreased purine excretion seen in many normal individuals after allopurinol administration, but is similar to the response seen in patients with a deficiency of hypoxanthine phosphoribosyltransferase' activity (10) .
The PP-ribose-P content of erythrocytes from the patient was 5.3 nmol/ml in the control specimen. It was unchanged (5.1 nmol/ml) after the administration of 800 mg of allopurinol per day for four days.
This also is differentfrom the response observed in control subjects, since in whom allopurinol normally produces a decreased PP-ribose-P content of eryth- Urinary excretion of parines and pyrimidines. Table 2 gives results of studies performed with the analyzer.
On a purine-free diet and in the absence of drugs, J.P. excreted 137 mg of xanthine and 44 mg of hypoxanthine per day. The xanthine/hypoxanthine ratio (by wt) in the urine during the control period was 4.6. The same ratio for three control subjects on a purine-free diet was 0.7 (7). After 800 mg of allopurinol per day had been administered for four days, urinary xanthine increased to 344 mg and hypoxanthine decreased to 37 mg. This resulted in a further increase in the xanthine/hypoxanthine ratio to 9.3. In three control subjects, allopurinol therapy was associated with a xanthine to hypoxanthine ratio of 3.3. Allopurinol was identified in the urine of the patient during administration of this drug. In addition, oxipurinol, the major metabolite of allopurinol, has been tentatively identified in this urine sample.
Orotic acid and orotidine excretion were also quantitated in the patient's urine and these results are recorded in Table 2 . No detectable (<2 mg per day) orotic acid or orotidine was found in his urine or in that of control subjects.
However, after the administration of allopurinol, the patient's excretion of both orotic acid and orotidine markedly increased (47 and 88 mg per day, respectively).
This response is qualitatively similar to that seen in normal subjects (12) .
Discussion
The diagnosis of xanthinuria was documented in this patient by the demonstration that xanthine oxidase activity was markedly diminished in jejunal and rectal mucosa (3 G+on.
In,.
Ad.n,n.
G+on,n. Previous studies in other individuals with xanthinuria have suggested that there is extensive re-utilization of purine bases in this disorder (13) (14) (15) . This is probably a result of the increased concentration of hypoxanthine.
Both hypoxanthine and xanthine can be converted to purine ribonucleotides by the transferase enzyme, while uric acid cannot be salvaged by this pathway because it is not a substrate for it (Figure 1) . The demonstration that hypoxanthine is a better substrate than xanthine for the transferase of human origin explains why it is re-utilized to a greater extent than is xanthine (13) (14) (15) . This also explains why the excretion of xanthine is roughly fivefold that of hypoxanthine ( be true, because allopurinol did not decrease total purine excretion or erythrocyte PP-ribose-P content in J.P. Both of these metabolic responses depend on functional activity of the transferase, as evidenced by the failure to observe either effect of allopurinol in patients with a genetic deficiency of this enzyme (10, 11) . Activity of the transferase is normal in J.P., so one cannot attribute this failure to exhibit these effects of allopurinol to a deficiency of this enzyme. In accord with the reasoning presented above it seems more likely that the enzyme in this subject with xanthinuria is virtually saturated with hypoxanthine and xanthine in vivo and thus is relatively unavailable for the conversion of allopurinol to allopurinol ribonucleotide.
It is interesting to note that administration of allopurinol to individuals with normal xanthine oxidase activity results in a change in xanthine and hypoxanthine excretion that is qualitatively similar to that observed in the subject with xanthinuria.
There are several lines of evidence to suggest that this patient has residual xanthine oxidase activity present in vivo. The administration of allopurinol to this subject caused a further increase in the excretion of xanthine relative to hypoxanthine.
This could be the result of a reduction in the residual xanthine oxidase activity and an accentuation of the phenomenon described above. If the tentative identification of oxipurinol in the urine of J.P. can be confirmed, this would provide additional support for the presence of a residual amount of xanthine oxidase activity in vivo, because allopurinol is metabolized to oxipurinol by xanthine oxidase. However, we cannot exclude the possibility that the oxidation of allopurinol to oxipurinol was catalyzed by bacteria in the gut rather than by a low xanthine oxidase activity in vivo, because no parenteral preparation of allopurinol is currently available. The direct demonstration of a low degree of xanthine oxidase activity in extracts from jejunal and rectal mucosa provides the final evidence to support this hypothesis. Considering all of this evidence together, we think it likely that there is at least some functional residual xanthine oxidase activity present in this subject.
Administration of allopurinol to normal and gouty subjects results in a marked increase in orotic acid and orotidine excretion (12) . The mechanism responsible for this is not completely understood, but it is thought to be a consequence of the inhibition of one or more of the steps in de novo pyrimidine biosynthesis, i.e., the reactions catalyzed by orotate phosphoribosyltransferase (EC 2.4.2.10)and orotidylic decarboxylase (EC 4.1.1.23). One potential explanation for this effect of allopurinol is its inhibition of xanthine oxidase. The present study would seem to exclude this possibility, however, because J.P. did not exhibit orotic aciduria or orotidinuria before allopurinol was begun. In fact, the demonstration of orotic aciduria and orotidinuria in J.P. after allopurinol administration suggests that allopurinol or one of its metabolites is responsible for the increase in pyrimidine excretion observed under these circumstances.
